{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:28Z","timestamp":1787841328661,"version":"build-2784847793"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T00:00:00Z","timestamp":1404950400000},"content-version":"vor","delay-in-days":1013,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND AND OBJECTIVES:<\/jats:title>\n                    <jats:p>Bendamustine has been recently approved for the treatment of low-grade lymphoproliferative disorders. There is little data on the effectiveness or toxicity of this drug outside the trial setting. This is the first report on the use of bendamustine from the Indian subcontinent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SETTINGS AND DESIGN:<\/jats:title>\n                    <jats:p>Retrospective descriptive analysis of response and side effects of bendamustine in eight patients with chronic lymphocytic leukemia and eight patients with follicular lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Data was collated from a review of case records. We examined any association between side effects and clinical parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>The median age of patients was 52 years and three-quarters had received prior treatment with alkyl -ators or fludarabine. Three different protocols of bendamustine were used (single agent, in combination with rituximab or in combination with vincristine and prednisolone). The overall response rate was 80% (47% complete response, 33% partial response, and 20% progressive disease). The drug was well tolerated with very few grade 3\/4 toxicities. More than half the patients (9\/16) developed a characteristic erythematous, papular skin rash that resolved after completion of chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Bendamustine is a safe and useful addition to the drug arsenal against lymphoproliferative disorders. A peculiar skin rash was the commonest side effect noted in Indian patients treated with this drug.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5144\/1658-3876.2011.157","type":"journal-article","created":{"date-parts":[[2014,7,16]],"date-time":"2014-07-16T11:43:48Z","timestamp":1405511028000},"page":"157-160","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Preliminary experience with the use of bendamustine"],"prefix":"10.4103","volume":"4","author":[{"given":"Baswantrao","family":"Malipatil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanth","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Sundersingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenali","family":"Gnana Sagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.5144\/1658-3876.2011.157_bb0005","doi-asserted-by":"crossref","first-page":"7456","DOI":"10.1158\/1078-0432.CCR-08-3041","article-title":"Bendamustine in B-cell Malignancies: The new 46-year-old kid on the block","volume":"15","author":"Gandhi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.5144\/1658-3876.2011.157_bb0010","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximabrefractory indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter, singleagent study","volume":"26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.5144\/1658-3876.2011.157_bb0015","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.5144\/1658-3876.2011.157_bb0020","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1200\/JCO.2008.20.8389","article-title":"Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia","volume":"27","author":"Knauf","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.5144\/1658-3876.2011.157_bb0025","first-page":"2596","article-title":"Bendamustine plus rituximab versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III study of the study group indolent lymphomas (StiL)","volume":"112","author":"Rummel","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"12","key":"10.5144\/1658-3876.2011.157_bb0030","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.5144\/1658-3876.2011.157_bb0035","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.5144\/1658-3876.2011.157_bb0040","unstructured":"Treanda [package insert] Available from: http:\/\/www.treanda.com\/pdf\/TREANDA_final_PI.pdf (accessed on 2011 May 5th)."},{"issue":"7","key":"10.5144\/1658-3876.2011.157_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D385N6C9JF","article-title":"Severe cutaneous interface drug eruption associated with bendamustine","volume":"16","author":"Alamdari","year":"2010","journal-title":"Dermatology Online Journal"},{"key":"10.5144\/1658-3876.2011.157_bb0050","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood.V26.3.257.257","article-title":"Exaggerated delayed hypersensitivity to mosquito bites in chronic lymphocytic leukaemia","volume":"26","author":"Weed","year":"1965","journal-title":"Blood"},{"key":"10.5144\/1658-3876.2011.157_bb0055","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1001\/archderm.135.12.1503","article-title":"Insect bite-like reaction in patients with hematologic malignant neoplasms","volume":"135","author":"Barzilai","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.5144\/1658-3876.2011.157_bb0060","series-title":"Adverse drug reactions","article-title":"Drug-induced skin reactions","author":"Lee","year":"2006"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387611500020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387611500020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201104040-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:50Z","timestamp":1787838590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201104040-00006"}},"subtitle":["a peculiar skin rash as the commonest side effect"],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.5144\/1658-3876.2011.157","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}